Athenex to acquire kuur therapeutics to expand cell therapy development with off-the-shelf engineered car-nkt platform

Buffalo, n.y., may 04, 2021 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its orascovery platform, today announced that it has acquired kuur therapeutics, inc., the leading developer of off-the-shelf car-nkt cell immunotherapies for the treatment of solid and hematological malignancies.
ATNX Ratings Summary
ATNX Quant Ranking